Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Sabine Kayser, Konstanze Doehner, Juergen Krauter, Heinz A. Horst, Marie von Lilienfeld-Toal, Ulrich Germing, Katharina Goetze, Michael Pfreundschuh, Walter Fiedler, MD, Daniela Spaeth, Silja Groner, Brigitte Schlegelberger, Gudrun Goehring, Arnold Ganser, MD, Hartmut Doehner, Richard F. Schlenk

Blood (2009) 114 (22): 2621.

https://doi.org/10.1182/blood.V114.22.2621.2621

Published: 2009

Journal Articles

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Blood (2009) 114 (22): 578.

https://doi.org/10.1182/blood.V114.22.578.578

Published: 2009

Journal Articles

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Thorsten Zenz, Sonja Häbe, Tina Denzel, Julia Mohr, Dirk Winkler, Andreas Bühler, Antonio Sarno, Silja Groner, Daniel Mertens, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (13): 2589–2597.

https://doi.org/10.1182/blood-2009-05-224071

Published: 2009

Includes: Supplemental data

Journal Articles

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

Sabine Kayser, Richard F. Schlenk, Martina Correa Londono, Frank Breitenbuecher, Kerstin Wittke, Juan Du, Silja Groner, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner, for the German-Austrian AML Study Group (AMLSG)

Blood (2009) 114 (12): 2386–2392.

https://doi.org/10.1182/blood-2009-03-209999

Published: 2009

Journal Articles

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Juergen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz H. Truemper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 329.

https://doi.org/10.1182/blood.V112.11.329.329

Published: 2008

Journal Articles

Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1

Sabine Kayser, Richard F. Schlenk, Frank Breitenbücher, Martina Porebski, Kerstin Wittke, Juan Du, Silja Groner, Daniela Spaeth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner

Blood (2008) 112 (11): 2514.

https://doi.org/10.1182/blood.V112.11.2514.2514

Published: 2008

Journal Articles

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

Marie-Luise Hütter, Konstanze Döhner, Ingo G.H. Schmidt-Wolf, Francisco Del Valle, Björn Heydrich, Wolfgang Heit, Walter Fiedler, Michael Pfreundschuh, MD, PhD, Gudrun Russ, Martin Bentz, Aruna Raghavachar, Detlef Haase, MD, PhD, Wolfram Brugger, MD, Katharina Götze, Silja Groner, Hartmut Döhner, Richard Schlenk

Blood (2008) 112 (11): 559.

https://doi.org/10.1182/blood.V112.11.559.559

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Stephan Stilgenbauer, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Jürgen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz Trümper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2007) 110 (11): 3120.

https://doi.org/10.1182/blood.V110.11.3120.3120

Published: 2007

Journal Articles

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

Richard F. Schlenk, MD, Konstanze Döhner, MD, Michael Kneba, MD, Francesco del Valle, MD, Frank Hartmann, MD, Heinz Kirchen, MD, Elisabeth Koller, MD, Katharina Götze, MD, Jörg Th. Fischer, MD, Marianne Habdank, Daniela Späth, Silja Groner, Andrea Corbacioglu, Axel Benner, MSC, Stefan Fröhling, Hartmut Döhner

Blood (2007) 110 (11): 297.

https://doi.org/10.1182/blood.V110.11.297.297

Published: 2007

Journal Articles

Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.

Richard F. Schlenk, MD, Konstanze Döhner, MD, Silja Groner, Peer C. Hartmann, Jürgen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD

Blood (2007) 110 (11): 1836.

https://doi.org/10.1182/blood.V110.11.1836.1836

Published: 2007

Journal Articles

Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).

Verena I. Gaidzik, MD, Marianne Habdank, Simone Moschny, Silja Groner, Daniela Spath, Jurgen Krauter, MD, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Hartmut Dohner, MD, Richard F. Schlenk, Konstanze Dohner, MD

Blood (2007) 110 (11): 364.

https://doi.org/10.1182/blood.V110.11.364.364

Published: 2007

Journal Articles

The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.

Sabine Kayser, MD, Konstanze Döhner, MD, Jürgen Krauter, MD, Daniela Späth, Silja Groner, Brigitte Schlegelberger, MD, Gudrun Göhring, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2007) 110 (11): 881.

https://doi.org/10.1182/blood.V110.11.881.881

Published: 2007

Journal Articles

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Richard F. Schlenk, MD, Martin Bommer, MD, Mathias Schmid, MD, Stefan Fröhling, MD, Katrin Lehmann, Silja Groner, Rainer Hann, Jürgen Krauter, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Martin Göttlicher, MD, Hartmut Döhner, MD

Blood (2005) 106 (11): 2800.

https://doi.org/10.1182/blood.V106.11.2800.2800

Published: 2005

NARROW

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.

Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).

The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only